A clinical evaluation of the efficacy and tolerability of isradipine in the treatment of hypertension in a Chinese population
Publication in refereed journal

Full Text

Times Cited

Other information
AbstractThe efficacy and tolerability of isradipine (1.25 and 2.5 mg BID) were assessed in a placebo-controlled open trial in 50 Chinese subjects of varying ages (mean ± SD age 64 ± 11 years, range 40 - 79 years). Significant reductions in blood pressure were achieved with both dosages of isradipine, and the overall responder and normalization rates were 68% and 40%, respectively. No age-related changes in efficacy were demonstrated. There were no changes in hematological or biochemical parameters, chest x-ray, or electrocardiographic findings. The incidence of side effects was not different from that on placebo. These findings are similar to those reported in Caucasian subjects.
All Author(s) ListWoo J., Chan T.Y.K., Critchley J.A.J.H.
Journal nameAdvances in Therapy
Volume Number7
Issue Number6
PublisherHealth Communications, Inc.
Place of PublicationUnited States
Pages362 - 368
LanguagesEnglish-United Kingdom

Last updated on 2021-18-09 at 23:36